Chilton Capital Management LLC Has $41.34 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Chilton Capital Management LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 58.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 372,849 shares of the biopharmaceutical company’s stock after buying an additional 137,531 shares during the period. Gilead Sciences accounts for approximately 1.5% of Chilton Capital Management LLC’s portfolio, making the stock its 20th biggest holding. Chilton Capital Management LLC’s holdings in Gilead Sciences were worth $41,338,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC acquired a new stake in Gilead Sciences during the 1st quarter valued at $25,000. Activest Wealth Management increased its holdings in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences during the second quarter valued at approximately $27,000. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences in the 1st quarter valued at $29,000. Finally, Colonial Trust Advisors lifted its stake in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. TD Cowen boosted their price target on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Royal Bank Of Canada lifted their price target on shares of Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday, October 8th. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the company from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research note on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.61.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the sale, the chief executive officer directly owned 595,725 shares in the company, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,500 shares of company stock valued at $8,281,540 in the last three months. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.2%

Shares of NASDAQ GILD opened at $120.94 on Friday. The stock has a market capitalization of $150.06 billion, a P/E ratio of 24.09, a P/E/G ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The company has a 50-day moving average price of $115.47 and a 200-day moving average price of $111.07. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.